Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables - Net: 2009-2024

Historic Receivables - Net for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $81.9 million.

  • Ironwood Pharmaceuticals' Receivables - Net rose 58.00% to $120.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.4 million, marking a year-over-year increase of 58.00%. This contributed to the annual value of $81.9 million for FY2024, which is 36.57% down from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Receivables - Net stood at $81.9 million, which was down 36.57% from $129.1 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Receivables - Net registered a high of $145.8 million during FY2020, and its lowest value of $81.9 million during FY2024.
  • In the last 3 years, Ironwood Pharmaceuticals' Receivables - Net had a median value of $129.1 million in 2023 and averaged $113.7 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first surged by 232.12% in 2020, then tumbled by 36.57% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Receivables - Net (Yearly) stood at $145.8 million in 2020, then declined by 5.35% to $138.0 million in 2021, then dropped by 5.80% to $130.0 million in 2022, then declined by 0.68% to $129.1 million in 2023, then slumped by 36.57% to $81.9 million in 2024.